BioPharma Dive January 24, 2025
The Trump administration is bringing new instability to a sector already grappling with a shaky market as well as new threats like competition from China.
As the first major drug industry conference each year, the J.P. Morgan Healthcare Conference is regularly described as a barometer of expectations for the year ahead.
This year, JPM delivered the dealmaking analysts and investors always say they hope to see: Johnson & Johnson agreed to buy Intra-Cellular Therapies for nearly $15 billion, while GSK and Eli Lilly announced smaller deals involving private biotechnology...
Today's Sponsors
Today's Sponsor